Loading stock data…
$0.07
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States.
Azitra, Inc. in the Healthcare sector is trading at $0.07 with a market capitalization of $10M. Wall Street consensus targets $0.67 (2 analysts), implying a +837.1% move over the next 12 months. The stock is currently near its 52-week low of $0.05, remaining 64.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.42M↑ | -$3.93M↓ | -$2.23M↑ | -$2.77M↑ | -$2.87M |
| Net Income | -$3.35M↑ | -$3.93M↓ | -$2.23M↑ | -$2.76M↑ | -$2.89M |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04,...